Retina/Vitreous News

Oral gildeuretinol acetate did not meet the primary endpoint of geographic atrophy lesion growth rate in a phase 3 study, according to a press release from Alkeus Pharmaceuticals.

Avacincaptad pegol may help postpone driving restrictions or loss of driving eligibility in patients with geographic atrophy, according to a post hoc analysis of the GATHER1 and GATHER2 trials.

ATSN-201 received orphan drug designation from the FDA for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

In this video, Barbara Blodi, MD, discusses long-term data on geographic atrophy growth rates in treatment-naive patients with age-related macular degeneration.

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

The FDA granted 510(k) clearance for OCT angiography on the robotic Maestro2 OCT color fundus camera system, according to a press release from Topcon Healthcare.

In this edition, enrollment and dosing complete in phase 1 trial of AIV007, popular benchmarks in clinical practice guidelines and more.

Viridian Therapeutics reported positive topline data from the phase 3 THRIVE clinical trial of veligrotug for the treatment of active thyroid eye disease.

Patients with neovascular age-related macular degeneration who experienced catastrophic vision loss after subretinal hemorrhage were linked to longer anti-VEGF treatment duration and shorter time from prior injection.